ArticleCase reports in surgery2025
Spontaneous Regression (SR) of Male Breast Cancer (MBC): A Rare Case Highlighting Diagnostic Pitfalls and Management Caution.
Article in Case reports in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Male breast cancer (MBC) is rare, accounting for only 1.8% of all breast cancer cases diagnosed globally. However, there is a rising trend in its incidence over the past decades. Spontaneous regression (SR) of a tumor, on the other hand, is a rare but well-documented phenomenon. Case Presentation: We reported a case of MBC that showed SR in the surgical specimen after the histopathologic diagnosis of invasive breast cancer in the core needle biopsy sample. A 58-year-old gentleman presented with a palpable left retroareolar mass, nipple retraction and intermittent pain for 2 months. Imaging and histopathological examination (HPE) confirmed an estrogen- and progesterone-receptor-positive, HER-2 negative invasive carcinoma, which was treated with left mastectomy with axillary clearance (MAC). Intraoperatively, no breast mass was palpable, and SR of the tumor was reported for the surgical sample. Conclusion: This case not only emphasizes the rarity of MBC but also draws attention to the exceptional phenomenon of SR in invasive carcinoma. Recognition of such rare events underscores the importance of cautious decision-making, multidisciplinary management, and further research into the biological and immunological mechanisms underlying tumor regression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.